451 D Street
5th Floor Suite 501
Boston, MA 02210
United States
857-209-0050
https://elicio.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 32
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Mr. Robert T. Connelly | CEO, President & Director | 612k | S.O. | 1960 |
Dr. Christopher M. Haqq M.D., Ph.D. | Executive VP, Head of Research & Development and Chief Medical Officer | 589k | S.O. | 1966 |
Prof. Darrell J. Irvine Ph.D. | Co-Founder, Consultant, Board Observer & Chairman of Scientific Advisory Board | S.O. | S.O. | S.O. |
Mr. Brian Piekos | Chief Financial Officer | S.O. | S.O. | 1975 |
Mr. Michael DiVecchia | Senior Vice President of Operations & Human Resources | S.O. | S.O. | S.O. |
Dr. Peter DeMuth Ph.D. | Chief Scientific Officer | S.O. | S.O. | 1986 |
Ms. Megan C. Filoon | General Counsel, Secretary & Compliance Officer | S.O. | S.O. | S.O. |
Ms. Esther Welkowsky | Senior Vice President of Clinical Development | S.O. | S.O. | S.O. |
Ms. Joy Seymour | VP & Head of Regulatory Affairs | S.O. | S.O. | S.O. |
Dr. Thian Kheoh Ph.D. | Senior Vice President of Biometrics | S.O. | S.O. | S.O. |
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops a pipeline of novel immunotherapies for the treatment of cancer. Its lead product candidate is ELI-002, a multivalent lymph nodetargeted AMP peptide vaccine that is in Phase II clinical trial to target seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company is also developing ELI-007, a multivalent lymph nodetargeted AMP peptide vaccine to target mutant v-raf murine sarcoma viral oncogene homolog B1 gene mutations found in solid tumors; and ELI-008, a multivalent lymph nodetargeted AMP peptide vaccine to target p53 hotspot mutations. The company is headquartered in Boston, Massachusetts.
L’ISS Governance QualityScore de Elicio Therapeutics, Inc. en date du 1 juin 2024 est 8. Les scores principaux sont Audit : 9; Société : 6; Droits des actionnaires : 8; Compensation : 9.